B-type natriuretic peptide (BNP) and ProBNP: Role of emerging markers to guide therapy and determine prognosis in cardiovascular disorders

American Journal of Therapeutics

Volumn 15, Issue 2, 2008, Pages 150-156

  Godkar, Darshan ^a,b   Bachu, Kalyan ^a   Dave, Bijal ^a   Niranjan, Selva ^a   Khanna, Ashok ^a  

^a Maimonides Medical Center   (United States)

^b Department of Internal Medicine ^*  (United States)

Author keywords

BNP; Myocardial infarction; ProBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; MYOGLOBIN; TROPONIN T;

CARDIAC GRAFT REJECTION; CARDIOVASCULAR DISEASE; CUSHING SYNDROME; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEALTH CARE COST; HEALTH HAZARD; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERALDOSTERONISM; KIDNEY FAILURE; LIVER CIRRHOSIS; LUNG EMBOLISM; MITRAL VALVE REGURGITATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDITIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; SYMPTOM; THORAX RADIOGRAPHY;

BIOLOGICAL MARKERS; HEART DISEASES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 41349087144     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31815af96f     Document Type: Review

References (70)

1. Heart Disease and Stroke Statistics - 2006 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Available at: http://circ.ahajournals.org/cgi/content/short/113/6/ e85#R35-171600. Accessed December 18, 2007.
2. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: A manifestation of coronary artery disease. Circulation. 1998;97:282-289.
3. Deedwania PC. The key to unraveling the mystery of mortality in heart failure: an integrated approach. Circulation. 2003;107:1719-1721.
4. Kistorp C. Risk stratification in secondary prevention: advances in multimarker profiles, or back to basics? Circulation. 2006;114:184-186.
5. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599-2610.
6. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003;108:2317-2322.
7. Morrow DA, Rifai N, Sabatine MS, et al. Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. Clin Chem. 2003. 49:1396-1398.
8. Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004;44:335-339.
9. Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med. 1992;327:146-150.
10. Seino Y, Ogata K, Takano T, et al. Use of awhole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: Comparison with rapid troponin Tand myoglobin tests. Am J Med. 2003;115:185-190.
11. Madsen LH, Christensen G, Lund T, et al. Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: The ASSENT-2 troponin substudy. Circ Res. 2006;99:1141-1147.
12. Ohman EM, Armstrong PW, White HD, et al. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol. 1999;84:1281-1286.
13. Storrow AB, Lindsell CJ, Han JH, et al. Discordant cardiac biomarkers: frequency and outcomes in emergency department patients with chest pain. Ann Emerg Med. 2006;48:660-665.
14. Bonarjee VV, Omland T, Nilsen DW, et al. Left ventricular volumes, ejection fraction, and plasma proatrial natriuretic factor (1-98) after withdrawal of enalapril treatment initiated early after myocardial infarction. CONSENSUS II Multi-Echo Study Group. Br Heart J. 1995;73:506-510.
15. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998;97:1921-1919.
16. Blankenberg S, McQueen MJ, Smieja M, et al. Comparative impact of multiple biomarkers and N-Terminal probrain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006;114:201-208.
17. Sanz G, Castaner A, Betriu A, et al. Determinants of prognosis in survivors of myocardial infarction: A prospective clinical angiographic study. N Engl J Med. 1982;306:1065-1070.
18. Starling MR, Crawford MH, Henry RL, et al. Prognostic value of electrocardiographic exercise testing and noninvasive assessment of left ventricular ejection fraction soon after acute myocardial infarction. Am J Cardiol. 1986;57:532-537.
19. Grimm W, Glaveris C, Hoffmann J, et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: design and first results of the Marburg Cardiomyopathy Study. Pacing Clin Electrophysiol. 1998;21:2551-2556.
20. Grimm W, Christ M, Bach J, et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation. 2003;108:2883-2891.
21. Klein H, Auricchio A, Reek S, et al. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol. 1999;83:91D-97D.
22. Theal M, Demers C, Mckelvie RS. The role of angiotensin II receptor blockers in the treatment of heart failure patients. Congest Heart Fail. 2003;9:29-34.
23. MacCarthy PA, Kearney MT, Nolan J, et al. Prognosis in heart failure with preserved left ventricular systolic function: prospective cohort study. Br Med J. 2003;327:78-79.
24. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92:843-849.
25. Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol. 2003;42:1793-1800.
26. Gardner RS, Ozalp F, Murday AJ, et al. N-terminal probrain natriuretic peptide. a new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003;24:1735-1743.
27. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330-337.
28. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635-641.
29. de Lemos JA, Morrow DA. Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application? Circulation. 2002;106:2868-2870.
30. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9-13.
31. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003;107:2786-2792.
32. Galvani M, Ottani F, Oltrona L, et al. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation. 2004;110:128-134.
33. Hamm CW. Cardiac biomarkers for rapid evaluation of chest pain. Circulation. 2001;104:1454-1456.
34. Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993;88:82-91.
35. Horio T, Shimada K, Kohno M, et al. Serial changes in atrial and brain natriuretic peptides in patients with acute myocardial infarction treated with early coronary angioplasty. Am Heart J. 1993;126:293-299.
36. Arakawa N, Nakamura M, Aoki H, et al. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology. 1994;85:334-340.
37. Brown AM, Sease KL, Robey JL, et al. The Impact of B-Type natriuretic peptide in addition to troponin I, creatine kinase-MB, and myoglobin on the risk stratification of emergency department chest pain patients with potential acute coronary syndrome. Ann Emerg Med. 2007;49:153-163.
38. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014-1021.
39. Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond). 1995;88:551-556.
40. Sabatine MS, Morrow DA, de Lemos JA, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004;44:1988-1995.
41. Tateishi J, Masutani M, Ohyanagi M, et al. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol. 2000;23:776-780.
42. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106:2913-2918.
43. Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996;93:1963-1969.
44. Talwar S, Squire IB, Downie PF, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J. 2000;21:1514-1521.
45. Young JB, Correia NG, Francis GS, et al. Testing for B-type natriuretic peptide in the diagnosis and assessment of heart failure: what are the nuances? Cleve Clin J Med. 2004;71(Suppl 5):S1-S17.
46. Smith MW, Espiner EA, Yandle TG, et al. Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. J Endocrinol. 2000;167:239-246.
47. Hall C. Essential biochemistry and physiology of (NT-pro) BNP. Eur J Heart Fail. 2004;6:257-260.
48. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316-322.
49. Januzzi JL Jr. Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure. Cleve Clin J Med. 2006;73:155-157.
50. Ogawa A, Seino Y, Yamashita T, et al. Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome. Circ J. 2006;70:1372-1378.
51. Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NTproBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf). 1997;47:287-296.
52. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 2003;41:1264-1272.
53. Richards AM, Nicholls MG, Yandle TG, et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart. 1999;81:114-120.
54. Gill D, Seidler T, Troughton RW, et al. Vigorous response in plasma N-terminal pro-brain natriuretic peptide (NT-BNP) to acute myocardial infarction. Clin Sci (Lond). 2004;106:135-139.
55. Ranjith N, Pegoraro RJ, Naidoo DP, et al. Prognostic value of N-terminal-pro-brain natriuretic peptide measurements in patients with acute coronary syndromes. Cardiovasc J S Afr. 2006;17:60-66.
56. Omland T, de Lemos JA, Morrow DA, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 2002;15;89:463-465.
57. Chen AA, Wood MJ, Krauser DG, et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J. 2006;27:839-845.
58. Troughton RW, Prior DL, Frampton CM, et al. Usefulness of tissue doppler and color M-mode indexes of left ventricular diastolic function in predicting outcomes in systolic left ventricular heart failure (from the ADEPT study). Am J Cardiol. 2005;96:257-262.
59. Tung RH, Garcia C, Morss AM, et al. Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med. 2004;32:1643-1647.
60. O'Donoghue M, Chen A, Baggish AL, et al. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Card Fail. 2005;11(5 Suppl):S9-S14.
61. Krauser DG, Lloyd-Jones DM, Chae CU, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J. 2005;149:744-750.
62. Maisel AS, Krishnaswamy P, Nowak RM, et al. Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
63. Kragelund C, Gronning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352:666-675.
64. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106:2913-2918.
65. Sabatine MS, Morrow DA, de Lemos JA, et al. Multi-marker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760-1763.
66. Heart Disease and Stroke Statistics - 2006 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Available at: http://circ.ahajournals.org/cgi/content/short/113/6/ e85#R35-171600. Accessed December 18, 2007.
67. Health Care Financing Review, 2003 Medicare and Medicaid Statistical Supplement. Available at: www.cms.hhs.gov/HealthCareFinancingReview/ 12_2003_Edition.asp TopOfPage. Accessed December 19, 2007.
68. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647-654.
69. Siebert U, Januzzi JL Jr, Beinfeld MT, et al. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol. 2006;98:800-805.
70. Maisel AS, Bhalla V, Braunwald E. Cardiac biomarkers: a contemporary status report. Nat Clin Pract Cardiovasc Med. 2006;3:24-34.